1009 related articles for article (PubMed ID: 20838997)
1. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
3. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Park KC; Kim SW; Park JH; Song EH; Yang JW; Chung HJ; Jung HJ; Suh JS; Kwon HJ; Choi SH
Cancer Sci; 2011 Feb; 102(2):343-50. PubMed ID: 21159061
[TBL] [Abstract][Full Text] [Related]
4. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Luong QT; O'Kelly J; Braunstein GD; Hershman JM; Koeffler HP
Clin Cancer Res; 2006 Sep; 12(18):5570-7. PubMed ID: 17000694
[TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
7. Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.
Chien CW; Yao JH; Chang SY; Lee PC; Lee TC
Toxicol Appl Pharmacol; 2011 Nov; 257(1):59-66. PubMed ID: 21889949
[TBL] [Abstract][Full Text] [Related]
8. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Chang H; Jeung HC; Jung JJ; Kim TS; Rha SY; Chung HC
Breast Cancer Res Treat; 2011 Jan; 125(1):55-63. PubMed ID: 20224928
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
Knutson AK; Welsh J; Taylor T; Roy S; Wang WL; Tenniswood M
Oncol Rep; 2012 Mar; 27(3):849-53. PubMed ID: 22159450
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
12. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
13. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
Tong A; Zhang H; Li Z; Gou L; Wang Z; Wei H; Tang M; Liang S; Chen L; Huang C; Wei Y
Cancer Chemother Pharmacol; 2008 Apr; 61(5):791-802. PubMed ID: 17593366
[TBL] [Abstract][Full Text] [Related]
14. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
Dietrich CS; Greenberg VL; DeSimone CP; Modesitt SC; van Nagell JR; Craven R; Zimmer SG
Gynecol Oncol; 2010 Jan; 116(1):126-30. PubMed ID: 19875160
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression.
Noro R; Miyanaga A; Minegishi Y; Okano T; Seike M; Soeno C; Kataoka K; Matsuda K; Yoshimura A; Gemma A
Cancer Sci; 2010 Jun; 101(6):1424-30. PubMed ID: 20384633
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
[TBL] [Abstract][Full Text] [Related]
19. Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.
Yamamoto S; Tanaka K; Sakimura R; Okada T; Nakamura T; Li Y; Takasaki M; Nakabeppu Y; Iwamoto Y
Anticancer Res; 2008; 28(3A):1585-91. PubMed ID: 18630516
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines.
Shen J; Huang C; Jiang L; Gao F; Wang Z; Zhang Y; Bai J; Zhou H; Chen Q
Biochem Pharmacol; 2007 Jun; 73(12):1901-9. PubMed ID: 17445779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
